JP2012525837A5 - - Google Patents

Info

Publication number

JP2012525837A5

JP2012525837A5 JP2012509109A JP2012509109A JP2012525837A5 JP 2012525837 A5 JP2012525837 A5 JP 2012525837A5 JP 2012509109 A JP2012509109 A JP 2012509109A JP 2012509109 A JP2012509109 A JP 2012509109A JP 2012525837 A5 JP2012525837 A5 JP 2012525837A5

Authority

JP

Japan

Prior art keywords

virus

influenza

seq

rna

item

Prior art date

2010-05-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 38
• 241000700605 Viruses Species 0.000 claims description 19
• 239000000523 sample Substances 0.000 claims description 14
• 108091034117 Oligonucleotide Proteins 0.000 claims description 9
• 108020004707 nucleic acids Proteins 0.000 claims description 9
• 102000039446 nucleic acids Human genes 0.000 claims description 9
• 150000007523 nucleic acids Chemical class 0.000 claims description 9
• 229960003971 influenza vaccine Drugs 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 239000002245 particle Substances 0.000 claims description 7
• 206010022000 influenza Diseases 0.000 claims description 6
• 241000712461 unidentified influenza virus Species 0.000 claims description 5
• 239000000427 antigen Substances 0.000 claims description 4
• 102000036639 antigens Human genes 0.000 claims description 4
• 108091007433 antigens Proteins 0.000 claims description 4
• 238000004113 cell culture Methods 0.000 claims description 4
• 238000000855 fermentation Methods 0.000 claims description 4
• 230000004151 fermentation Effects 0.000 claims description 4
• 238000001914 filtration Methods 0.000 claims description 4
• 108020000999 Viral RNA Proteins 0.000 claims description 3
• 230000003321 amplification Effects 0.000 claims description 3
• 238000003745 diagnosis Methods 0.000 claims description 3
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
• 108091093088 Amplicon Proteins 0.000 claims description 2
• 101710085938 Matrix protein Proteins 0.000 claims description 2
• 101710127721 Membrane protein Proteins 0.000 claims description 2
• 238000011529 RT qPCR Methods 0.000 claims description 2
• 102000006382 Ribonucleases Human genes 0.000 claims description 2
• 108010083644 Ribonucleases Proteins 0.000 claims description 2
• 239000003153 chemical reaction reagent Substances 0.000 claims description 2
• 238000004587 chromatography analysis Methods 0.000 claims description 2
• 238000011026 diafiltration Methods 0.000 claims description 2
• 238000011049 filling Methods 0.000 claims description 2
• 238000003306 harvesting Methods 0.000 claims description 2
• 230000002779 inactivation Effects 0.000 claims description 2
• 238000002156 mixing Methods 0.000 claims description 2
• 238000012544 monitoring process Methods 0.000 claims description 2
• 238000000746 purification Methods 0.000 claims description 2
• 238000003762 quantitative reverse transcription PCR Methods 0.000 claims description 2
• 239000000725 suspension Substances 0.000 claims description 2
• 238000000108 ultra-filtration Methods 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 1